Tag Archives: BIO CEO & Investor Conference

Fireside Chat with Allergan CEO, David Pyott

David Pyott

Day two of the 16th Annual BIO CEO & Investor Conference​ kicked off with a Fireside Chat featuring one of the longest tenured pharma CEOs, David E.I. Pyott, Chairman of the Board & Chief Executive Officer, Allergan. The Chat, moderated by Seamus Fernandez, Managing Director, Major and Specialty Pharmaceuticals, Leerink Partners LLC, explored the multi-specialty healthcare model that Allegran has found success in which few realize is not just ophthalmology. Allergan has also found success in neurosciences, medical dermatology, dermal fillers and urologics. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Open Communication Helps Reduce Rare Disease Drug Development Risk

115x76allisonMparks

One of the most important keys to successful relationships – be it in life or rare disease drug development – is open, honest and frequent communication, according to a panel of rare disease experts speaking at the Therapeutic Workshop: “Balancing the Rick-Reward in Rare Disease Drug Development” at the BIO CEO & Investor Conference in New York on Monday. Without engaging the key groups at the right time and the right manner, companies entering this Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Sanofi’s Chris Viehbacher: Trust, Respect Key in Pharma-Biotech Partnerships

33713_Viehbacher_100x100 copy

How can large pharmaceutical and small biotech companies form mutually beneficial partnerships that harness the strengths of each side in order to bring new therapies to patients? Sanofi CEO and Genzyme Chairman Chris Viehbacher shared his thoughts on that question and several other topics, including the growing importance of emerging markets, at a Fireside Chat at the 16th Annual BIO CEO & Investor Conference on Monday. He reflected that as the leader of a big pharma Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

What’s New in RNAi Therapeutics?

87881842

At the 16th Annual BIO CEO & Investor Conference​, Monday morning’s therapeutic workshop, “Delivering the (RNAi) Goods,” featured a panel discussion moderated by Thomas Wei, senior research analyst at Jeffries LLC. The panel gave investors a peek into the novel approaches utilized by four leading companies in this area: Dicerna Pharmaceuticals, Arrowhead Research Corporation, Alnylam Pharmaceuticals, and Regulus Therapeutics. RNAi therapeutics, which include gene silencing, exon skipping, and mircroRNA therapy, are a promising area in the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

4 Tips for Building a Successful Biotech: Richard Pops of Alkermes at #BIOCEO14

Pops

The 16th Annual BIO CEO & Investor Conference opened with a fireside chat between Richard F. Pops, Chairman & Chief Executive Officer of Alkermes, and David Gluckman of Lazard. The candid discussion gave biotech CEOs a peek in to the story of Alkermes, yielding useful guidance on building a successful, agile company ready for a changing marketplace. Here are some of the highlights: Be world class in a specific area of science. “In our company, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,